C-YDUCGenflow Biosciences
SIRT6 gene therapy, AAV delivery, longevity therapeutics
editinggene therapy
Loading
Loading section...0-100 chain-logic scale · 15 dimensions · scored on public evidence
←All companiesC-YDUC
C-YDUCC-YDUCSIRT6 gene therapy, AAV delivery, longevity therapeutics
0-100 chain-logic scale · 15 dimensions · scored on public evidence
Genflow Biosciences Ltd (LSE:GENF, OTCQB:GENFF, FRA:WQ5) CEO Dr Eric Leire joined Proactive's Stephen Gunnion to discuss a landmark collaboration with Acuitas Therapeutics, the lipid nanoparticle specialist whose technology underpinned some of the most successful COVID-19 vaccines ever made. Leire described it as one of the most significant partnerships Genflow has signed, giving the company access to the gold standard in mRNA delivery technology - fully funded by Acuitas, with no cash cost and no dilution to shareholders. The collaboration will combine Genflow's proprietary SIRT6 payload with Acuitas' clinically validated LNP platform, generating preclinical data to support future clinical development and partnering discussions. Leire positioned the deal as a potential inflexion point, transitioning Genflow from a science story into a tangible clinical and commercial opportunity. For more videos like this, visit Proactive's YouTube channel, give this video a like, subscribe to the
Genflow Biosciences Ltd (LSE:GENF, OTCQB:GENFF, FRA:WQ5) CEO Dr Eric Leire talked with Proactive's Stephen Gunnion about the company receiving the first tranche of a €4 million non-dilutive grant from Wallonia and what it means for the advancement of its GF-1002 MASH programme. Leire confirmed that the initial instalment has now been received, calling it a “landmark moment” for the company. He emphasised that the funding provides “a significant boost to our cash runway with zero equity cost to investors,” allowing Genflow to focus fully on advancing its science without dilution to shareholders. The grant directly supports the company’s MASH programme, targeting advanced metabolic dysfunction-associated steatohepatitis, which Leire described as one of the most significant unmet medical needs of this generation. He noted that in advanced stages of the disease, “there is simply no treatment option other than liver transplant,” positioning the company’s gene therapy approach as a potenti
Overview: In this talk, Dr. Eric Leire, CEO and Founder of Genflow Biosciences, addresses one of the central challenges in longevity medicine: why decades of robust ageing research have yielded so few clinically meaningful interventions. Drawing on Genflow's experience as the first longevity-focused biotech listed on the London Stock Exchange (LSE: GENF), Dr. Leire explores the scientific, regulatory, and strategic considerations that shape the translation of longevity biology into the clinic. The Talk: The Oxford Society of Ageing and Longevity presents this lecture on the translational pipeline of longevity therapeutics. Dr. Leire critically examines the limitations of traditional murine (mouse) models in predicting human outcomes, the regulatory frameworks that govern early-stage longevity therapeutics, and Genflow's innovative rationale for conducting a longevity clinical trial in aged companion dogs — exploring the scientific, ethical, and societal implications of this approach a
Genflow Biosciences Ltd (LSE:GENF, OTCQB:GENFF) CEO Dr Eric Leire talked with Proactive's Stephen Gunnion about the company’s key programs and upcoming catalysts as it enters what management expects to be a pivotal year. Leire discussed why 2026 is shaping up as “a year of catalysts” for the company, with particular focus on the dog ageing trial, progress in MASH, and the group’s approach to partnerships and licensing. Leire explained that the dog longevity study is the nearest catalyst, with the trial expected to be unblinded shortly and early efficacy readouts anticipated in the near term. While safety has already been confirmed, the study remains blinded, meaning efficacy results are still unknown. The first data will focus on biological age, measured using a methylation clock, with a more detailed analysis of muscle biopsies and mitochondrial function to follow. According to Leire, “this trial could be very important for our shareholders, because it will trigger a deal with an an
Genflow Biosciences Ltd (LSE:GENF, OTCQB:GENFF) CEO Dr Eric Leire talked with Proactive's Stephen Gunnion about the company’s progress in its canine gene therapy trial targeting sarcopenia. Leire confirmed that the dosing phase has now been completed with no adverse effects, calling it a key milestone in de-risking the SIRT6 programme for potential pharma partners and investors. He said, “We demonstrated some kind of safety, with the full dosing, we had to observe no side effect, no adverse side effect, even minor event.” Leire explained the study’s scientific rigour, highlighting its randomised, controlled and blinded design using aged dogs not previously involved in clinical trials. This, he said, addresses a major unmet need in the life extension field, with industry experts previously considering such a study “impossible to do.” Looking ahead, efficacy data is expected in January, with analysis focused on multiple endpoints. These include mitochondrial function, clinical data, m
Genflow Biosciences CEO Dr Eric Leire speaks to Proactive about the company’s expanding IP strategy and its potential to unlock treatments for age-related and metabolic diseases. Learn more about how Genflow is leveraging Sirtuin-6 technology to drive innovation and attract pharma partnerships.
Genflow Biosciences PLC (LSE:GENF, OTCQB:GENFF) CEO Dr Eric Leire talked with Proactive's Stephen Gunnion about the company's latest milestone – the granting of its second European patent, which he says is a key part of Genflow’s intellectual property strategy in the longevity and metabolic disease space. Leire explained that the patent strengthens the company’s position by providing protection not only for the composition of matter but also for specific methods of use, all focused around Sirtuin-6, a core element in the company’s technology platform. He stated, “We’re building a layer portfolio that combines property, construct, delivery method, and specific applications for human health.” The new patent covers a variant for NASH (non-alcoholic steatohepatitis), but Leire noted that the Sirtuin-6 platform has broader relevance for multiple age-related diseases, including glaucoma, sarcopenia, and other metabolic conditions. He emphasised that strong IP is essential for entering int
Genflow Biosciences CEO Dr Eric Leire speaks to Proactive about the company’s expanding IP strategy and its potential to unlock treatments for age-related and metabolic diseases. Learn more about how Genflow is leveraging Sirtuin-6 technology to drive innovation and attract pharma partnerships.
Dr. Eric Leire, CEO of Genflow Biosciences explains how the Company is using dogs as a translational model for aging therapies, which serves both scientific validation and commercial entry into the growing pet longevity market, creating dual revenue and research pathways. #GENF #Bioscence #Biotech
Genflow Biosciences PLC (LSE:GENF, OTCQB:GENFF) CEO Dr Eric Leire talked with Proactive's Stephen Gunnion about the company's achievement in securing a major European patent. The newly published patent strengthens Genflow’s intellectual property around its sirtuin 6 variant — a core element of its longevity therapeutic platform. Leire described the development as a “major step,” noting it creates a strong defensive barrier against competition. “We are now in the final phase of securing our cornerstone intellectual property,” he said. This form of protection is vital for small biotech firms like Genflow, particularly as it enhances the company’s attractiveness to potential pharmaceutical partners. Leire emphasised that, with this patent in place, Genflow now has the IP foundation needed to engage pharma players seriously. He explained that the company is unlikely to fund Phase 3 trials independently, making partnerships essential. “You need to have a strong IP protection. Now we have
Dr. Eric Leire, CEO of Genflow Biosciences, joined focusIR’s Katie Pilbeam to discuss how the company is using aging dogs as both a scientific model and a strategic entry into the pet longevity market, aiming to translate those findings into human aging therapies. He explains how their work targets age-related diseases like MASH, sarcopenia, and glaucoma by focusing on the SIRT6 pathway, which plays a key role in aging across species. Leire emphasizes the importance of extending healthspan, not just lifespan, and balancing investor enthusiasm with the scientific realities and long timelines of aging research. In this interview, investors will also hear: - How the company is using dogs as a translational model for aging therapies, which serves both scientific validation and commercial entry into the growing pet longevity market, creating dual revenue and research pathways. - Why the company is targeting major unmet medical needs such as MASH, sarcopenia, and glaucoma through its
Genflow Biosciences PLC (LSE:GENF, OTCQB:GENFF) CEO Dr Eric Leire talked with Proactive's Stephen Gunnion about the company’s upcoming clinical trial application in Europe for its MASH (metabolic dysfunction-associated steatohepatitis) therapy, GF-1002. Leire explained that Genflow is prioritising the European Medicines Agency over the FDA as it seeks clinical trial authorisation (CTA) for its GF-1002 programme. He emphasised the importance of this milestone in building company value, stating: “To have proof of efficacy in humans is super important for us to move as fast as possible to clinical trial authorisation.” The company is working with Belgian-based CDMO Exothera on the CMC part of the filing, and Leire said results so far have exceeded expectations. He also highlighted the dual-CRO strategy involving Physiogenex and Accelera to address both early and late-stage MASH models. This approach aims to provide flexibility when engaging with regulators about the most effective path
Genflow Biosciences PLC (LSE:GENF, OTCQB:GENFF) CEO Dr Eric Leire talked with Proactive's Stephen Gunnion about the company’s significant progress toward securing European patents for its SIRT6 variant, marking a major milestone. The patent, which mirrors an earlier US patent, covers the composition of matter for the SIRT6 gene variant, a discovery made alongside the University of Colombia, Rochester University, and the Albert Einstein School of Medicine. Leire explained that the SIRT6 variant was identified through research on a unique population of Jewish Ashkenazi centenarians, showing a mutation that boosts SIRT6 activity. Highlighting the gene's role in managing DNA damage and epigenomic changes, he noted, "We are in a safer position because we secure one of the very important competitive advantages over other longevity companies." Genflow plans to apply this SIRT6 gene variant to age-related conditions such as Non-Alcoholic Steato Hepatitis (NASH), sarcopenia, and glaucoma, uti
Genflow Biosciences Plc CEO Dr. Eric Leire joined Steve Darling from Proactive to share news the company has announced it has secured €4,026,525 in non-dilutive financial support from the Wallonia region, which will aid in the development of Genflow’s lead gene therapy, GF-1002. This therapy is being developed for the treatment of Metabolic Associated Steatohepatitis (MASH), a severe liver disease. The Wallonia region's financial backing demonstrates the recognition of Genflow's pioneering work in gene therapy. Dr. Leire explained that the support includes a non-reimbursable research grant covering 70% of Genflow’s research expenses and a recoverable advance funding 55% of the development costs, which will be repaid upon the commercialization of GF-1002. This funding is expected to cover three years of development, and Genflow plans to secure the remaining funds required to fulfill its share of the project over this period. This marks a significant step forward in the fight against MA
Genflow Biosciences PLC (LSE:GENF, OTCQB:GENFF) CEO Dr Eric Leire talked with Proactive about the company's progress and financial results for the first half of 2024. Leire highlighted Genflow's unique financial strategy, focusing on R&D while minimising operational costs. He emphasised Genflow's success in advancing five key longevity programs, including the MASH liver program and research into Werner syndrome using synthetic organoids. In addition, Leire revealed that Genflow successfully raised non-dilutive grant funding and brought institutional investors onto it share register, a crucial step after the company's IPO during the pandemic. It also continues to push forward with clinical trials, including a promising dog study aimed at improving pet health and lifespan. Looking ahead, the company is set to achieve critical milestones, including progressing to clinical trials and refining its discussions with regulatory agencies. Visit Proactive's YouTube channel for more interview
Genflow Biosciences PLC (LSE:GENF, OTCQB:GENFF) CEO Dr Eric Leire talked with Proactive's Stephen Gunnion about the company receiving €395,847, representing 50% of the Exofastrack research grant from the Government of Wallonia in Belgium's Advanced Therapy Medicinal Products (ATMPs). Leire explained that the grant, a non-dilutive, non-reimbursable subsidy, supports Genflow and EXO Biologics' three-year scientific program. Covering 80% of the expenses, the grant will be used for working capital. The program will deliver a therapeutic product composed of exosomes encapsulating an AAV or mRNA encoding SIRT6. The exosome therapy will be designed to target liver fibrosis (MASH) and Werner Syndrome, an accelerated ageing disease. Discussing the program, Leire highlighted the potential of exosomes in addressing unmet medical needs and mentioned the innovative photo operation technique for loading exosomes. If successful, this technique could have significant commercial implications beyond
Zak Mir talks to Dr Eric Leire, CEO Genflow Biosciences, in the wake of the company, which is rapidly becoming the major European exponent in the successful development of therapeutic longevity solutions for the prevention of age-related diseases, announcing it has raised, through its broker Capital Plus Partners, £715,000. This was to add and broaden the number of institutional investors in Genflow, including Premier Miton.
Many of us strive towards living long lives; but just as health risks grow as we age, we might say it’s quite a challenge. Dr. Eric Leire, a thought leader in the area of longevity and life extension, is aiding this goal. He is the CEO of Genflow Biosciences, a longevity gene therapy biotech that is driven by one mission: to deliver therapeutics that potentially halt or slow the aging process in humans and dogs. In this episode, he joins Doctor Awesome to tell us more about their origin story and the science of what they are doing. Dr. Leire also talks about health span versus life span, the role of AI in this revolution in aging, and how they are tackling the longevity issue with gene therapy. Beyond the technology, Dr. Leire then gives some great lifestyle tips on what we can do to maximize the likelihood of getting the long life we want. So follow along to this great episode and hear about the future of aging. #future, #futureisbright, #longevity, #genetherapy, #lifespan
Many of us strive towards living long lives; but just as health risks grow as we age, we might say it’s quite a challenge. Dr. Eric Leire, a thought leader in the area of longevity and life extension, is aiding this goal. He is the CEO of Genflow Biosciences, a longevity gene therapy biotech that is driven by one mission: to deliver therapeutics that potentially halt or slow the aging process in humans and dogs. In this episode, he joins Doctor Awesome to tell us more about their origin story and the science of what they are doing. Dr. Leire also talks about health span versus life span, the role of AI in this revolution in aging, and how they are tackling the longevity issue with gene therapy. Beyond the technology, Dr. Leire then gives some great lifestyle tips on what we can do to maximize the likelihood of getting the long life we want. So follow along to this great episode and hear about the future of aging. #future, #futureisbright, #longevity, #genetherapy, #lifespan
Genflow Biosciences PLC (LSE:GENF) CEO Dr. Eric Leire speaks to Thomas Warner from Proactive about the gene therapy company's work in the field of extending human longevity. He notes that the amazing advances made in advancing human lifespans over the last century have not been matched by a similar increase in people's healthspans, with many people spending the second half of their life plagued with various debilitating illnesses and conditions. "The purpose of our company is to increase the healthspan, that's the primary objective. If we can also increase the lifespan, fine... so we are a longevity company that's trying to extend healthspan and secondly maybe lifespan." He goes on to explain how Genflow Biosciences is going about its mission, revealing its most promising leads, before concluding by saying who else in the sector he admires. #ProactiveInvestors #genflow #genetics #longevity #genetherapy #biotech #biopharma #invest #investing #investment #investor #stockmarket #stock
Dr. Eric Leire, CEO of Genflow Biosciences PLC, recently announced exciting developments in the company's fight against nonalcoholic steatohepatitis (NASH), a liver disease that affects millions of people worldwide. Significant progress has been made in its pre-clinical program, targeting fat deposition, fibrosis, and liver cancer associated with NASH. The company has strengthened its Scientific Advisory Board with the addition of Professor Dr Sven Franque, an expert in NASH and regulatory authorities. Furthermore, Genflow has promoted Tamara Joseph as chairperson, reflecting their commitment to diversity and expanding their presence in the US market. They have also applied to trade on the OTC QB market, and Dr. Leire plans to increase their presence in the US. These advancements highlight Genflow's dedication to addressing the unmet need in NASH treatment. #ProactiveInvestors #GenflowBiosciences #LiverDisease #NashTreatment #MedicalAdvancements #ScientificInnovation #HealthcareIn
Genflow Biosciences PLC's (LSE:GENF) CEO Dr Eric Leire spoke to Proactive about an injection of funding from long-standing Estonian partner IVEX. The funding will allow Genflow to run an additional research programme without eating into any of its existing capital, he said. Dr Leire also spoke about some "extremely promising" data and the company's first-half results. #GenflowBiosciences #Estonia #longevity
Eric Leire, chief executive at Genflow Biosciences, joined Katie to talk about an international patent filed by the company. The new patent application is "very important" according to Leire as it concerns the composition of matter. Essentially, the patent makes it very difficult to go around the patent.
Genflow Biosciences PLC founder and chief executive Dr Eric Leire joins Proactive London to provide an update to investors four months after the long-life company’s initial public offer in London. He talks about the company’s cash runway to enable it to weather the current market storm, how it is “a beautiful position” in relation to opportunities in the biotech sector, and the importance of Genflow’s current pre-clinical work.
Eric Leire (CEO) Genflow Biosciences PLC (LSE:GENF) Presenting at the proactive One2One Virtual Forum - 20th January 2022 Genflow Biosciences PLC, a UK-based biotechnology company is developing gene therapies designed to target the ageing process and to reduce and delay the incidence of age-related diseases. This will be done through novel therapeutics targeting ageing in humans by using genetically modified adeno-associated virus (AAV) vectors to deliver copies of the SIRT6 gene variant that is found in centenarians. SIRT6 has already been shown to have improved capabilities to repair DNA damage. This will improve health spans (living healthier for longer) and potentially, life expectancy. Genflow primarily seeks to develop its lead compound, GF-1002, a recombinant self-complementary AAV containing a transgene encoding the cDNA (coding DNA) portion of a variant of the human SIRT6 gene found in centenarians, that has already yielded promising pre-clinical results.
For exclusive Stock Market news and interviews subscribe to our weekly newsletter http://weekly.share-talk.com/ GenFlow Biosciences is a biotechnology company dedicated to increasing our understanding of the factors that controls lifespan. We research, develop and commercialize therapeutic solutions to lengthen healthspan, the amount of time we live in good health. Our mission is to create biological interventions that enable longer and healthier lives.GENFLOW is dedicated to the development and commercialization of novel therapeutics targeting ageing in dogs and humans. Ageing is not a natural fatality. There is no rationale for a limited lifespan. Ageing can now be considered as a risk factor that we can treat. By treating ageing, we believe that GENFLOW can contribute to decrease healthcare costs and lessen the emotional and societal burden that comes with an ageing population.https://www.share-talk.com/eric-leire-chief-executive-officer-genflow-biosciences-interview/
At Ending Age-Related Diseases 2020, Dr. Eric Leire of Genflow Biosciences discussed his company, explaining what Genflow does and how it is funded. The company is intervening directly in the biology of aging, affecting SIRT6, which, like other sirtuins, is a known regulator of aging. The company intends to develop its SIRT6 plasmid as an epigenomic therapy that will affect downstream hallmarks of aging, potentially providing a broad-based solution to multiple age-related diseases. HOW CAN YOU SUPPORT US? ▀▀▀▀▀▀▀▀▀▀▀▀▀▀▀▀▀▀▀▀▀▀▀▀▀▀ LEAF / Lifespan.io is a 501(c)(3) nonprofit organization. Everything we've done thus far and everything we will do in the future is thanks to your support - please stand with us to fight the diseases of aging and increase healthy human lifespan. ► Support us with monthly donations by becoming a Lifespan Hero: https://www.lifespan.io/hero ► Make a one-time donation and learn about other ways to support us here: http://lifespan.io/support ► Learn more, and he
Genflow Biosciences PLC Announces Directorate Change - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Press Releases Genflow Biosciences PLC Announces Directorate Change January 19, 2026 | 6 min read Twitter LinkedIn Facebook Email Print THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE MARKET ABUSE REGULATION (EU) NO. 596/2014 AS IT FORM … rms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com . SOURCE: Genflow Biosciences PLC View the original press release on ACCESS Newswire Twitter LinkedIn Facebook Email Print Europe Executive appointments C-suite People ACCESS Newswire LATEST Layoff Tracker Genentech R&D cuts include longtime top exec June 12, 2026 · 59 min read · … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Genflow Biosciences PLC Announces Result of GM - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Press Releases Genflow Biosciences PLC Announces Result of GM March 2, 2026 | 2 min read Twitter LinkedIn Facebook Email Print Results of General Meeting LONDON, UK / ACCESS Newswire / March 2, 2026 / Genflow Biosciences Plc (LSE:GENF)(OTCQB:GENFF) ("Genflow" or "the Company") a leading European-based biotechnology comp … rms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com . SOURCE: Genflow Biosciences PLC View the original press release on ACCESS Newswire Twitter LinkedIn Facebook Email Print Europe ACCESS Newswire LATEST Layoff Tracker Genentech R&D cuts include longtime top exec June 12, 2026 · 59 min read · BioSpace Editorial Staff Manufacturing … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Genflow Biosciences PLC Announces Exercise of Warrants and Issue of Equity - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opini … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Press Releases Genflow Biosciences PLC Announces Exercise of Warrants and Issue of Equity May 8, 2026 | 3 min read Twitter LinkedIn Facebook Email Print THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS STIPULATED UNDER THE UK VERSION OF THE MARKET ABUSE REGULATION NO 596/2014 WHICH IS PART OF ENGLISH LAW BY VIRTUE OF TH … d by the Company in respect of this exercise. Admission and Total Voting Rights Application has been made for the Warrant Shares, which will rank pari passu in all respects with the existing Ordinary Shares of the Company, to be admitted to the FCA official list and to trading on the equity shares (transition) category of the Official List maintained by the FCA and to trading on the main market for listed securities of the LSE, which is expected to occur on or around 8.00 a.m … rms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com . SOURCE: Genflow Biosciences PLC View the original press release on ACCESS Newswire Twitter LinkedIn Facebook Email Print Europe ACCESS Newswire LATEST Layoff Tracker Genentech R&D cuts include longtime top exec June 12, 2026 · 59 min read · BioSpace Editorial Staff Manufacturing … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Genflow Biosciences PLC Announces Key SIRT6 Patent Application - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Re … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Press Releases Genflow Biosciences PLC Announces Key SIRT6 Patent Application May 15, 2025 | 2 min read Twitter LinkedIn Facebook Email Print LONDON, UNITED KINGDOM / ACCESS Newswire / May 15, 2025 / Genflow Biosciences Plc (LSE:GENF)(OTCQB:GENFF) ("Genflow" or "the Company"), the only publicly listed longevity company … announces that the Japanese Patent Office has advanced its SIRT6-related patent application (Application No. JP 2024515284) to the national examination phase. The application, titled "Variants of SIRT6 for Use in Preventing and/or Treating Age-Related Diseases," was originally filed on 13 May 2022 and is jointly owned by the University of Rochester, The Trustees of Columbia University in the City of New York, and Albert Einstein College of Medicine. Genflow holds the exclusiv … s a strategically important jurisdiction for Genflow, and advancing this patent application strengthens our global positioning as a leader in longevity gene therapy." Genflow continues to progress its preclinical and clinical programs targeting age-related pathologies using the SIRT6 gene variants. Contacts Genflow Biosciences Harbor Access Dr Eric Leire, CEO Jonathan Paterson, Investor Relations +32-477-495-881 +1 475 477 9401 [email protected] Corporate Br … rms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com . SOURCE: Genflow Biosciences PLC View the original press release on ACCESS Newswire Twitter LinkedIn Facebook Email Print Europe Patents ACCESS Newswire LATEST Layoff Tracker Genentech R
Genflow Biosciences PLC Announces Clinical Readiness Acceleration - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Press Releases Genflow Biosciences PLC Announces Clinical Readiness Acceleration July 24, 2025 | 5 min read Twitter LinkedIn Facebook Email Print Clinical Readiness Accelerates Across Genflow Biosciences Lead Programs LONDON, UK / ACCESS Newswire / July 24, 2025 / Genflow Biosciences Plc (LSE:GENF)(OTCQB:GENFF) ("Genflo … rms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com . SOURCE: Genflow Biosciences PLC View the original press release on ACCESS Newswire Twitter LinkedIn Facebook Email Print Europe Pipeline LATEST Layoff Tracker Genentech R&D cuts include longtime top exec June 12, 2026 · 59 min read · BioSpace Editorial Staff Manufacturing FDA im … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Genflow Biosciences PLC Announces Strategic Technology Collaboration - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Pr … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Press Releases Genflow Biosciences PLC Announces Strategic Technology Collaboration April 20, 2026 | 7 min read Twitter LinkedIn Facebook Email Print Genflow Biosciences Enters Strategic Technology Collaboration with Acuitas Therapeutics - Fully Funded, Non-Dilutive Access to World-Class LNP Delivery Platform LONDON, UK … rms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com . SOURCE: Genflow Biosciences PLC View the original press release on ACCESS Newswire Twitter LinkedIn Facebook Email Print Europe Collaboration mRNA ACCESS Newswire LATEST Layoff Tracker Genentech R&D cuts include longtime top exec June 12, 2026 · 59 min read · BioSpace Editorial … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Genflow Biosciences PLC Launches New Development Program - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Press Releases Genflow Biosciences PLC Launches New Development Program April 10, 2025 | 2 min read Twitter LinkedIn Facebook Email Print Genflow Biosciences Launches New Ophthalmology Development Program Signs MTA with Leading Ophthalmology Company LONDON, UK / ACCESS Newswire / April 10, 2025 / Genflow Biosciences Plc … rms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com . SOURCE: Genflow Biosciences PLC View the original press release on ACCESS Newswire Twitter LinkedIn Facebook Email Print Europe Gene therapy ACCESS Newswire LATEST Layoff Tracker Genentech R&D cuts include longtime top exec June 12, 2026 · 59 min read · BioSpace Editorial Staff … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Genflow Biosciences PLC Announces Preliminary Interim Results From Dog Study - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opi … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Press Releases Genflow Biosciences PLC Announces Preliminary Interim Results From Dog Study February 12, 2026 | 7 min read Twitter LinkedIn Facebook Email Print THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE MARKET ABUSE REGULATION (EU … rms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com . SOURCE: Genflow Biosciences PLC View the original press release on ACCESS Newswire Twitter LinkedIn Facebook Email Print Europe Pipeline Data ACCESS Newswire LATEST Layoff Tracker Genentech R&D cuts include longtime top exec June 12, 2026 · 59 min read · BioSpace Editorial Staff … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Genflow Biosciences PLC Announces International Patent Publication - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Pres … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Press Releases Genflow Biosciences PLC Announces International Patent Publication April 13, 2026 | 6 min read Twitter LinkedIn Facebook Email Print THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE MARKET ABUSE REGULATION (EU) NO. 596/201 … o announce the international publication of its Patent Cooperation Treaty (PCT) application, WO 2026/062177 A1, entitled "Variants of Sirtuin 6 for the Treatment of Muscular Diseases." The published PCT application relates to variants of SIRT6 for the prevention and treatment of muscular diseases, with particular focus on frailty syndrome and sarcopenia. The application describes compositions and methods involving SIRT6 variants, including nucleic acids, polypeptides, vectors … f Genflow Biosciences, commented: "The international publication of this patent application marks another important step in the expansion of Genflow's intellectual property portfolio. By extending our SIRT6 platform into muscular diseases such as frailty and sarcopenia, we are continuing to build strategic protection around areas of high unmet need and significant relevance to healthy ageing. This publication further strengthens our position as we advance the development and … rms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com . SOURCE: Genflow Biosciences PLC View the original press release on ACCESS Newswire Twitter LinkedIn Facebook Email Print Europe Patents Pipeline Data Intellectual property ACCESS Newswi
Genflow Biosciences and CER Sign Master Service Agreement to Strengthen Long-Term R&D Collaboration - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Press Releases Genflow Biosciences and CER Sign Master Service Agreement to Strengthen Long-Term R&D Collaboration May 28, 2025 | 2 min read Twitter LinkedIn Facebook Email Print LONDON, UK / ACCESS Newswire / May 28, 2025 / Genflow Biosciences Plc (LSE:GENF)(OTCQB:GENFF) ("Genflow" or "the Company"), the only publi … rms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com . SOURCE: Genflow Biosciences PLC View the original press release on ACCESS Newswire Twitter LinkedIn Facebook Email Print Europe Collaboration Gene therapy LATEST Layoff Tracker Genentech R&D cuts include longtime top exec June 12, 2026 · 59 min read · BioSpace Editorial Staff Ma … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Genflow Biosciences PLC Announces Receipt of First Tranche of Grant - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Pre … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Press Releases Genflow Biosciences PLC Announces Receipt of First Tranche of Grant March 2, 2026 | 5 min read Twitter LinkedIn Facebook Email Print THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE MARKET ABUSE REGULATION (EU) NO. 596/201 … irst instalment of €336,467 of the previously announced €4 million non-dilutive grant awarded by the Wallonia Region of Belgium, (see RNS dated 22 October, 2024 here .) The support package spans a three-year development programme and is aligned with Genflow's existing roadmap for GF-1002 in MASH. The grant will support the continued development of the Company's lead gene therapy candidate, GF-1002, with further instalments expected to be received in accordance with the agreed … to confirm receipt of the first instalment under the €4 million Wallonia Region grant. This initial funding supports the continued advancement of GF-1002 in MASH and strengthens our ability to execute against planned development milestones. We look forward to progressing the programme and receiving subsequent instalments in line with the agreed framework." Contacts Genflow Biosciences Harbor Access Dr Eric Leire, CEO Jonathan Paterson, Investor Relations +32-477-495-881 +1 47 … rms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com . SOURCE: Genflow Biosciences PLC View the original press release on ACCESS Newswire Twitter LinkedIn Facebook Email Print Europe Funding ACCESS Newswire LATEST Layoff Tracker Genentech R
%PDF-1.3 %��������� 4 0 obj > stream x�XMo�@�ﯘ�}谳���mSJH�*����J-����G�6V���\��o���o��>� H���� �F��@0�.��.��k �'e�B� �h�@}��A�>C����U������ Y(������%A��⓷���/P��Y�T,b�%E������.� ��HS l;R)�Ueyz��4(�y�V]� ~���sq���.�s�C`�0f�) ��������C� :y�� �C���h0�1�͗UǒU���W H�����Q�ȳ.��a"�e��A�7�پ�J���+�~���,=ƞ�)�5� ���VkH�a��v����܈ �E�.H�J�Ϻ��O� �L�M���A n�����`O��-��ឧ�i$�������)����-K8�S%]r�cy��YF�;c�٘iv���=� x���}�ݖn�Iv�M�t�e�dv~\�!k�ʭw�G�J;v�bH 9���a > endobj 5 0 obj > >> endobj 8 0 obj [ 9 0 R ] endobj 11 0 obj > stream x�\�r��}�WLޖB�����ŪHe��r�Z� \y%Qb"qi
Solvonis Therapeutics, hVIVO, OptiBiotix Health, Genflow Biosciences, Valereum, Tooru https://www.proactiveinvestors.com/companies/news/1086585/solvonis-therapeutics-hvivo-optibiotix-health-genflow-biosciences-valereum-tooru.html #Health #Pharmaceuticals #Biotech #Blockchain #Tokenisation #Food #Wellness | Proactive
Genflow CEO on promising SLAB trial data and next steps in dog trial https://www.proactiveinvestors.com/companies/news/1090194/genflow-ceo-on-promising-slab-trial-data-and-next-steps-in-dog-trial.html #Health #Pharmaceuticals #Biotech #Pets #Dogs #Veterinary | Proactive
Genflow Biosciences CEO on using dogs to fight aging | London South East posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in, you ag
Genflow and CER agree to long-term R&D collaboration - BioTuesdays Kilmer Lucas Want to be featured? Never any costs or strings attached. Let’s talk! Home Features News Developments Executive Moves Markets Subscribe Contact Search Home Features News Developments Executive Moves Markets Subscribe Contact Search Search Developments Genflow and CER agree to long-term R&D collaboration May 28, 2025 Genflow Biosciences (LSE:GENF; OTCQB:GENFF) has announced the signing of a master service agreement (MSA) with closely held CER Groupe—a long-standing partner—to strengthen long-term research an
Asset->js('assets/js/cookie-banner', null, false) }}" as="script">--> --> Genflow Biosciences strikes LNP delivery deal with mRNA vaccine technology pioneer | LSE:GENF, OTCQB:GENFF @ element('Front/sign_in_out_buttons') --> AU UK USA AU CA Watch --> My Proactive Feed Alerts Subscriptions Bookmarks Settings Sign In News Browse Latest news IPOs Live Newsletters OTC Markets Quarterlies Small caps The Five at Five SpaceX stock surges in hotly anticipated market debut 02:12 13 Jun --> The Small Cap Weekly Wrap: IPOs, resource upgrades, biopharma milestones and more... 14:22 12 Jun --> Has Crypto lo … s to identify and eradicate tumours 10:38 12 Jun --> Pilbara Gold chases bigger prize as Mt York grows into major WA development story 10:37 12 Jun --> AuMEGA Metals: Can Newfoundland's next major gold discovery emerge from Cape Ray? 10:37 12 Jun --> Prescient Therapeutics seeks to provide new tools for clinicians in combating cancer 10:45 11 Jun --> Can Queensland's Taroom Trough become Australia's next major gas basin? 14:07 10 Jun --> Watch Companies Browse
You need to enable JavaScript to run this app. Loading...
Genflow Biosciences PLC Announces Notice of AGM - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Press Releases Genflow Biosciences PLC Announces Notice of AGM June 4, 2026 | 2 min read Twitter LinkedIn Facebook Email Print Notice of Annual General Meeting and Board Changes LONDON, UK / ACCESS Newswire / June 4, 2026 / Genflow Biosciences Plc (LSE:GENF)(OTCQB:GENFF) ("Genflow" or "the Company") an emerging leader i … rms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com . SOURCE: Genflow Biosciences PLC View the original press release on ACCESS Newswire Twitter LinkedIn Facebook Email Print Europe Events ACCESS Newswire LATEST Layoff Tracker Genentech R&D cuts include longtime top exec June 12, 2026 · 59 min read · BioSpace Editorial Staff Manufa … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Genflow announces ophthalmology program based on SIRT6 centenarian gene technology | BioWorld BioWorld. Link to homepage. BioWorld BioWorld Science BioWorld Asia Data Snapshots Biopharma Medical technology Infographics: Dynamic digital data analysis Index insights NME Digest Special reports Infographics: Dynamic digital data analysis Ebola outbreak Hantavirus Trump administration impacts Med-tech outlook 2026 Under threat: mRNA vaccine research BioWorld at 35 Biopharma M&A scorecard Bioworld 2025 review BioWorld MedTech 2025 review BioWorld Science 2025 review Women's health China'
#glaucoma #sirt6 #blindness #genetherapy #genf #genff #genflow #aging #biotech | Genflow Biosciences (LON:GENF) (OTCQB:GENFF) LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to j … wo at AACR meeting with MilliporeSigma , named as the winners in the Innovation Award for their PURedit ® Cas9 Flexible/Precision Cytosine Base Editor kit.🏆 This off-the-shelf recombinant protein cytosine base editor enables flexible, transient cytosine base editing without double-strand breaks for safer gene editing and a variety of powerful applications in genetics research. #CiteAbAwards2026 View C2PA information 35 Like Comment Share Copy LinkedIn Facebook X To view or a
Market Research Reports and Consulting – Global Insight Services Anti-Aging Drugs Market Size, Growth, Trends and Forecast | Global Insight Services US: +1-833-761-1700 [email protected] Submit Queries Home Reports Automotive & Transportation Chemicals & Materials Consumer Goods Energy & Natural Resources Food & Beverages Manufacturing & Construction Medical Devices Pharmaceuticals Semiconductors & Electronics Technology, Media, & Telecom Services Syndicated Reports Custom reports Consulting Services Subscriptions Insights Analyst Insights Press … able | End User: Hospitals & Clinics, Home Care, Wellness Centers, Others | Application: Skin Care, Hair Care, Bone & Joint Health, Immune Health, Age-related Disorders, Others | Gender: Female, Male | Published Date : April 2026 Report Code : GIS33621 Number of Pages : 350 Industry : Pharmaceuticals Reports Summary Table of Contents Companies Research Methodology Request Sample --> The global Anti Aging Drugs Market is projected to grow from $55.9 billion in 2025 to … l, Injectable End User Hospitals & Clinics, Home Care, Wellness Centers, Others Application Skin Care, Hair Care, Bone & Joint Health, Immune Health, Age-related Disorders, Others Gender Female, Male The expanding aging population is a major driver for the anti-aging drugs market, as rising life expectancy and a growing elderly demographic increase demand for preventive and therapeutic interventions. According to global estimates, the population aged 60 and above is expected … d Congress (AMWC) in Monaco. In December 2025, Oisín Biotechnologies received a grant from the Methuselah Foundation to advance its fat reduction study in pigs. In October 2025, Calico Life Sciences received fast track designation for an investigational therapy targeting Autosomal Dominant Polycystic Kidney Disease. In April 2025, Genflow partnered with Heureka Labs to develop AI-driven gene therapy solutions. In August 2024, Aeovian Pharmaceuticals highlighted emerging anti- … 102.4 Billion CAGR 0.064 SEGMENTS COVERED Type, Form, Stage, Product, End User, Application, Gender ANALYSIS COVERAGE Market Forecast, Competitive Landscape, Drivers, Trends, Restraints, Opportunities, Value-Chain, PESTLE, Key Events, SWOT Analysis and Developments Research Scope Estimates and forecasts the overall market size across type, applic
Tietosuojavalintasi guce guce Tietosuojasi on meille tärkeää Yahoo on osa Yahoo-konserni Sivustot ja sovellukset, jotka omistamme ja joita operoimme, mukaan lukien Yahoo ja Engadget, sekä digitaalinen mainospalvelumme (Yahoo Advertising). Yahoo-konsernia . Kun käytät sivustojamme ja sovelluksiamme, käytämme evästekäytännöstämme ."> Evästeet Evästeiden (sekä vastaavien tekniikoiden, esimerkiksi verkkotallennuksen) avulla verkkosivustojen sovellusten ylläpitäjät voivat tallentaa ja lukea laitteesi tietoja. Lue lisää evästekäytännöstämme . evästeitä tarjotaksemme sivustomme ja sovelluksemme sinul
Genflow Biosciences PLC Announces Launch of AI-Powered Partnership - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Pres … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Press Releases Genflow Biosciences PLC Announces Launch of AI-Powered Partnership April 14, 2025 | 3 min read Twitter LinkedIn Facebook Email Print Genflow Biosciences Signs MSA with Heureka Labs, Launching AI-Powered Partnership in Gene Therapy Research LONDON, UNITED KINGDOM / ACCESS Newswire / April 14, 2025 / Genflo … nsional genomic data including RNA sequencing and gene expression profiles. The application of Heureka's AI technology is expected to enhance Genflow's ability to interpret complex biological datasets, enabling deeper insights into gene regulatory networks and systemic biological responses. These insights will be key to optimising therapeutic design and anticipating patient-specific outcomes. Genflow will retain all IP rights under the MSA. Initial efforts will support the Co … rms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com . SOURCE: Genflow Biosciences PLC View the original press release on ACCESS Newswire Twitter LinkedIn Facebook Email Print Europe Artificial intelligence ACCESS Newswire LATEST Layoff Tracker Genentech R&D cuts include longtime top exec June 12, 2026 · 59 min read · BioSpace Edito … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Genflow Biosciences to Attend J.P. Morgan Healthcare Conference WEBTRADE PREMIUM TRADING & INVESTING Trading Stocks Overnight Trading Options Index Options Futures ETFs OTC Margin Prediction Markets Sports Prediction Markets Investing Crypto New Cash Management -- APY Recurring Investing Retirement Accounts (IRAs) Fixed Income Money Market Funds Webull Advisors Platform Desktop App Mobile Apps Tools paperTrade Charts & Tools Vega New Open API Orderflow Chart LIVE QUOTES INSTITUTIONS HUB More from Webull News Community Corporate Connect Our Partners State Street CME Group Nasdaq Cboe Tr … ly exceed the initial required deposit. You need to complete an options trading application and get approval on eligible accounts. Please read the Characteristics and Risks of Standardized Options before trading options. All investments involve risk, and not all risks are suitable for every investor. The value of securities may fluctuate and as a result, clients may lose more than their original investment. The past performance of a security, or financial product does not gua … applies for oversized option orders. Relevant regulatory and exchange fees may apply. Please refer to our Fee Schedule for more details. No content on the Webull Financial LLC website shall be considered as a recommendation or solicitation for the purchase or sale of securities, options, or other investment products. All information and data on the website is for reference only and no historical data shall be considered as the basis for judging future trends. © 2026 Webull F
Genflow Biosciences Plc (LON: GENF) to pitch longevity gene therapy at JPM 2026 - Share Talk Home Company Information Company Enquiry Form FAQ Financial Podcasts Our Podcasts Our Policies Events News Automobiles, Parts & Engineering Blogs Business & Support Services Energy Financial Fintech Food & Beverages Healthcare Learning Manufacturing & Industrial Mining Podcasts Property & Retail Tech Special Features International Market News Malcy’s Blog Share Talk Small Cap Review Share Talk Weekly Energy Sector Share Talk Weekly Mining Sector Share Talk Weekly Stock Market Share
London Stock Exchange | London Stock Exchange | Genflow Biosciences (LON:GENF) (OTCQB:GENFF) LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in, you agree to Link
OTC Markets | Official site of OTCQX, OTCQB, OTCID and Pink Limited Markets You need to enable JavaScript to run this app.
RNS – Genflow Bioscience | Genflow Biosciences (LON:GENF) (OTCQB:GENFF) LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in, you agree to LinkedIn’s User Agreement … ce assays developed, validated, and clinically tested against a hard conference deadline, our California laboratory team delivered, ahead of schedule. 87 samples. 2 six-plex mIF assays. 9,000+ data points. 6 weeks. We know how important it is for early stage programs to receive their data, fast. Read the full case study here: https://buff.ly/KnzsoP2 #Biomarkers #MultiplexImmunofluorescence #ClinicalResearch #CellCarta #DigitalPathology …more 41 1 Comment Like Comment Share Co … ification and chemical tractability, as the recipient of the Biotech Innovators Award. Through access to lab space, shared infrastructure, and mentorship from scientific and business leaders, the award is designed to help accelerate the development of new therapies. This collaboration reflects a shared commitment to strengthening Canada’s life sciences ecosystem. Read our press release at https://bit.ly/4n7uzDg #AbbVieBiotechInnovatorsAward #LifeSciences #BioTechEcosystem 90
About – Genflow Bioscience Skip to main content Skip to footer Company About Leadership Careers Science Genflow BioScience Product Pipeline Clinical Programs Investors Investor Relations Advisers Committees Corporate Governance ESG RNS Major Shareholders News & Media Insights Publications Media Assets Search site Search × Contact About Genflow Biosciences plc is an emerging leader in the field of longevity research with R&D facilities in Belgium and a US office in Cambridge, MA, driven by one mission: to deliver therapeutics that potentially halt or slow the ageing process in hu
Zacks Small Cap Research - OTC Markets Hosts Virtual Investor Presentation with Eric Leire, Founder & CEO of Genflow Biosciences, and Brad Sorensen, Senior Analyst at Zacks SCR Skip to main content Skip to main content --> --> Home Analyst Bios News Research Reports Companies by Analyst Steven Ralston, CFA David Bautz, PhD Ann Heffron, CFA, CPA Tom Kerr, CFA Michael Kim Brian Lantier, CFA M. Marin Brad Sorensen, CFA Lisa Thompson John Vandermosten, CFA Ronald Wortel, MBA, P. Eng. Companies by Name Research Notes Distribution Institutional Distribution Retail Distribution Social Media RSS F … ior Equity Research Analyst with Zacks Small-Cap Research. Please note, you can submit questions to the presenter in the box to the left of the slides. You can also view the company's availability for one-on-one meetings through the scheduled meetings tab found on the conference platform. At this point, I'm very pleased to welcome Eric Leire, Founder and Chief Executive Officer of Genflow Biosciences, PLC, which trades on the OTCQB venture market under the symbol GENFF. Now, … cash anyway and the runway to do all that. We're not under pressure through our grant financing and the fact that we are a listed company. We have a long runway. But yes, we'll see what kind of deal we can have. It's now a very concentrated industry, the vet, so you don't have a lot of people to discuss with. EL: They're bigger and bigger. So it's difficult when a small company and, you know, partnership with a big company, and especially when you don't know the space. I will … nk you have? When are the human trials going to start? And do you have money to fund those trials, at least for the MASH? Kindly provide details so people can understand where you stand financially. EL: Yes. So, for MASH, we are now in the IND enabling phase. That means we do the talks and the GMP production. We applied for grants from Wallonia for this. It has been discussed, and the money has been accepted. We're still waiting for the money to be in the bank. As soon as we … start the clinical trial in Newman. We have the possibility, in addition to the grant every year, to have to issue 20% of new shares. There's a lot of appetite from, otherwise, from investors, and every year, we try to sell 20% of our shares, which gives us a lot of comfort for the very long term. We don't need any additional funding. EL: We have
- YouTube Info Presse Urheberrecht Kontakt Creator Werben Entwickler Impressum Verträge hier kündigen Nutzungsbedingungen Datenschutz Richtlinien & Sicherheit Wie funktioniert YouTube? Neue Funktionen testen © 2026 Google LLC
#sirt6 #biotech #aging #genf #genff | Genflow Biosciences (LON:GENF) (OTCQB:GENFF) LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in, you agree to LinkedIn’s Use
You Are Likely To Live Longer Than You Think: Day Two Of The 10th ARDD Meeting | Genflow Biosciences (LON:GENF) (OTCQB:GENFF) LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to j
Wave Pod Discover Library Get Wave AI Sign In Wave Pod AI summaries and full transcripts for the podcasts you already follow. Free, by Wave . Product How it works Browse podcasts Your library Company About Wave Privacy Terms Get Wave AI Download app WaveTube — YouTube summaries Contact Wave AI Tools AI Transcription App Speech to Text App Audio to Text Converter Audio Transcription Software AI Note Taking App AI Note Taker Meeting Notes App Meeting Transcription App AI Meeting Recording App Voice Recorder App Lecture Recording App Call Recording App Online Voice Recorder Transcribe Video to Te
Genflow Biosciences Plc (LSE:GENF) Company Update - Share Talk Home Company Information Company Enquiry Form FAQ Financial Podcasts Our Podcasts Our Policies Events News Automobiles, Parts & Engineering Blogs Business & Support Services Energy Financial Fintech Food & Beverages Healthcare Learning Manufacturing & Industrial Mining Podcasts Property & Retail Tech Special Features International Market News Malcy’s Blog Share Talk Small Cap Review Share Talk Weekly Energy Sector Share Talk Weekly Mining Sector Share Talk Weekly Stock Market Share Talk Week Ahead Stockmarket Ne … for the next 2.5 years without need for additional equity raises · Non-dilutive grant research award from the Wallonia region in Southern Belgium allowing the Company to further extend its cash runway to support commercialisation activities Operational highlights · Advancing pre-clinical programmes remain on-track. Moreover, clinical trials are expected to commence within an approximate 2-year timeframe which is in line with Company expectations · Signed a scientific research
Proactive - Interviews for investors Proactive - Interviews for investors Genflow Biosciences CEO on Acuitas collaboration: non-dilutive growth catalyst Episode Summary Genflow Biosciences Ltd (LSE:GENF, OTCQB:GENFF, FRA:WQ5) CEO Dr Eric Leire joined Proactive's Stephen Gunnion to discuss a landmark collaboration with Acuitas Therapeutics, the lipid nanoparticle specialist whose technology underpinned some of the most successful COVID-19 vaccines ever made. Leire described it as one of the most significant partnerships Genflow has signed, giving the company access to the gold standard in
Genflow Biosciences sets June 29 AGM, director exits | GENFF Stock News --> STOCK TITAN Login Sign up Login Sign up 0 HOME --> NEWS FEED Stock News Live Stock News Today Trending News AI news FDA Approvals Clinical Trials Crypto News Merger & Acquisitions Earnings Offerings IPO News Stock Splits Top News - Gainers Top News - Losers SEC FILINGS SEC Filings Live SEC Filings Today Form 4 - Insider Trading 8-K - Material Events 10-K - Annual Reports 10-Q - Quarterly Reports DEF 14A - Proxy Statements S-1 - IPO Registration S-3 - Shelf Registration STOCKS All Stock Themes AI Stocks Crypto Stocks Oi … rms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com . SOURCE: Genflow Biosciences PLC View the original press release on ACCESS Newswire FAQ When is the Genflow Biosciences (GENFF) 2026 AGM and where will it be held? The Genflow Biosciences 2026 AGM is scheduled for 11:00 a.m. on 29 June 2026 at One Heddon Street, London W1B 4BD. According to Genflow, AGM details, the
Chief Executive Officer of GenFlow Biosciences Interview – Genflow Bioscience Skip to main content Skip to footer Company About Leadership Careers Science Genflow BioScience Product Pipeline Clinical Programs Investors Investor Relations Advisers Committees Corporate Governance ESG RNS Major Shareholders News & Media Insights Publications Media Assets Search site Search × Contact Chief Executive Officer of GenFlow Biosciences Interview GenFlow Biosciences is a biotechnology company dedicated to increasing our understanding of the factors that controls lifespan. We research, develop
- YouTube Info Presse Urheberrecht Kontakt Creator Werben Entwickler Impressum Verträge hier kündigen Nutzungsbedingungen Datenschutz Richtlinien & Sicherheit Wie funktioniert YouTube? Neue Funktionen testen © 2026 Google LLC
Instagram Instagram Log In Sign Up Close Never miss a post from ageingandlongevity Sign up for Instagram to stay in the loop. Sign up Log in Tags ox.personalisedmed ageingandlongevity and ox.personalisedmed Department of Pharmacology More options ageingandlongevity Edited • 17w 🧬✨ Oxford friends + longevity nerds: this one’s for you. We’re hosting an event with @ox.personalisedmed and @genflowbio Join us for a talk about Genflow Biosciences: Translating longevity research to the bedside — an evening with Dr. Eric Leire (CEO & Founder, Genflow Biosciences) on what it takes to turn ageing
National Storage Mechanism | Additional information RNS Number : 8567K Genflow Biosciences PLC 30 May 2025 30 May 2025 Genflow Biosciences plc ("Genflow" or the "Company") Total Voting Rights Genflow Biosciences Plc (LSE:GENF) (OTCQB:GENFF) ("Genflow" or "the Company") announces that the total issued share capital of the Company as at 30 May 2025 consists of 453,547,942 ordinary shares of £0.0003 each, none of which are held in treasury. Therefore, the total number of voting rights in the Company is 453,547,942. The figure of 453,547,942 ordinary shares may be used … rms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com . RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the Lo
Genflow Biosciences PLC Announces Final Results - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Press Releases Genflow Biosciences PLC Announces Final Results April 30, 2026 | 2 min read Twitter LinkedIn Facebook Email Print THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE MARKET ABUSE REGULATION (EU) NO. 596/2014 AS IT FORMS PART … eld; pivotal studies initiated to support CTA filing; €4m non-dilutive Wallonia grant reaffirmed, with first tranche slated for May 2026. Strengthened global intellectual property position: SIRT6 patent family expanded through publications across Europe, China, and Japan, supporting long-term protection of the platform. Expanded platform and development capabilities: MSA signed with CER Groupe to support pre-IND development in a GxP-compliant environment; AI partnership with … rms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com . SOURCE: Genflow Biosciences PLC View the original press release on ACCESS Newswire Twitter LinkedIn Facebook Email Print Europe Pipeline Longevity Intellectual property ACCESS Newswire LATEST Layoff Tracker Genentech R&D cuts include longtime top exec June 12, 2026 · 59 min read ·&nbs … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Eric Patterson Leire MD - Executive Bio, Work History, and Contacts - Equilar ExecAtlas Request a Demo Engage Executives. Unlock Deals. ExecAtlas delivers real-time insight into who-knows-who, paving the way for warm introductions that create opportunities. Search for an Executive Trusted by Industry Leaders Trusted by Industry Leaders Featured Profile Eric Patterson Leire MD CHIEF EXECUTIVE OFFICER at Genflow Biosciences plc Eric Patterson Leire MD 's Executive Work History Current CHIEF EXECUTIVE OFFICER , CHIEF EXECUTIVE OFFICER Equilar on 09/21/2025 Genflow Biosciences plc Past To view Eri
Eric Leire: Latest Articles, Analysis and Profile | South China Morning Post Eric Leire + FOLLOW Dr Eric Leire, MD, MBA, is a former researcher at Harvard, Pfizer, Schering Plough and Pharmacia. He is CEO of Genflow Biosciences, a UK-based biotech company delivering therapeutics that potentially halt or slow the ageing process. Dr Eric Leire, MD, MBA, is a former researcher at Harvard, Pfizer, Schering Plough and Pharmacia. He is CEO of Genflow Biosciences, a UK-based biotech company delivering therapeutics that potentially halt or slow the ageing process. Languages Spoken: English Show more T
Genflow Biosciences PLC Company Profile | GENF | GB00BP2C3V08 | Fidelity Genflow Biosciences PLC (GENF) Industry Biotechnology Deal This stock can be held in an Investment ISA, SIPP and Investment Account Sell 2.05p Buy 2.20p Change arrow-down -0.025p (-1.16%) Prices updated at 12 Jun 2026 , 15:34 BST | Prices minimum 15 mins delay | Prices in GBX Genflow Biosciences PLC is a preclinical biotechnology company focused on the development of biological interventions (namely gene therapies) which are aimed at tackling the effects of aging, potentially slowing or halting the aging process and so re … shareholders Owner name chevron-l-regular chevron-r-regular No. of shares 1741 Fund Services S.A. 470,633 Plutos- Wealth One 470,633 Miton Asset Management Limited - Premier Miton UK Smaller Companies - Director dealings Date chevron-l-regular chevron-r-regular Action 11 Mar 2026 Purchase 11 Mar 2026 Purchase 16 Oct 2025 Purchase Please note that past performance is not a reliable indicator of future returns. Important Information Investment values, and income from investmen
GENFLOW BIOSCIENCES PLC - Annual Report 2024 | FinancialReports.eu Skip to main content Markdown filings API · 412-page report → ~3,200 tokens · Markdown filings API. Get API access → Financial Reports Companies Filings Customers Solutions Hedge Funds Asset Managers Analytics Platforms Academic Research API Log in Sign up Get API access Financial Reports × Search Browse Companies Filings Customers API Solutions Hedge Funds Asset Managers Analytics Platforms Academic Research Log in Get API access isMobile = window.innerWidth Open assistant AI assistant Sign in to chat with this filing The assi … igned to target MASH and Werner Syndrome. During 2024, the Company has received grant funding of totalling €777,281 in respect of 50% these projects, with the further 50% financial support committed in the first half of 2026, subject to spending over the working capital requirements. In 2024, other operating income totalling £320,471 has been recognised in the Consolidated Statement of Comprehensive Income in relation to these grants. Funding In October 2024, we received offi … port, subject to the Company meeting certain conditions, which will continue to fund the ongoing development of Genflow's lead gene therapy for the treatment of MASH. The Wallonia region's financial support highlights the growing recognition of Genflow's innovative work in gene therapy. The financial support comprises non-reimbursable research grants and a recoverable advance, repayable to the Wallonia region upon commercialisation. This funding, is expected to cover three ye … UK institution, participate in this fundraise. The Company completed a further fund raise in March 2025 with a major institution for an equity investment totalling £434,083 (before expenses), in order to accelerate the Company's planned 2025 programs including launching a clinical trial in aged dogs. 2025 During 2025, the Company plans to continue advancing its existing research programs, along with embarking on an exciting clinical trial focused on aged dogs. In early 2025, … research phase. During the year ended 31 December 2024, the Company recognised grant income of £320,471 (2023: £169,854) relating to the two non-dilutive and non-reimbursable research grants from the Government of Wallonia in Belgium’s Advanced Therapy Medicinal Products (ATMPs), the remaining proportion of the €777,281 cash received in relation
%PDF-1.3 %��������� 3 0 obj > stream x�X�n�0��+&]鶒9�պI7.�[ݚ� �P������9Tl �,9���4�8|��3 ��㼭Ѹ��4�G�� ��������Û�(��� �P� �� 9=+���uN�t8�����xJ.�՜&��Q�䣍Ǚ ���l��섩�E7 z ��w� M,:+DAI�� > endobj 4 0 obj > /Font > >> endobj 12 0 obj > stream x��wTS��Ͻ7��" %�z �;HQ�I�P��&vDF)VdT�G�"cE ��b� �P��QDE�k �5�ޚ��Y�����g�}P���tX�4�X���\���X��ffG�D���=���HƳ��.�d��,�P&s���"7C$ E�6 � A1�v�jpԁz�N�6p\W� p �G@ ��K0ށi���A����B�ZyCAP8�C���@��&�*���CP=�#t�]���� 4�}���a ���ٰ; G���Dx����J�>����,�_@��FX�DB�X$!k�"��E�����H�q���a���Y��bVa�b … ���lHf����������Z��&�@�6�5J�nե�}� Ƌ�{���|i���x��� ��a���l 7����Q�V�W:Q� nn�RFp�B�p���_�cp�G �b�k�o�8}� G�X�ɺ�+��S s��8D�c�ps2yK�Z6�1���d�&�3�錵鄘�p�J� Cfxt-��]�P��%���筡M&��qw������1�Y��n `��������+� endstream endobj 191 0 obj > endobj 193 0 obj > /Font > >> endobj 197 0 obj > stream x��ْ,9r���)���Rg���ܳgDvM/v�^P,g�jݴiF&��H�3�=����#���S��me�Q ���@ "�s����\�替u˟��\����D�z��EY�t��aӭN��O]��ay�^�����O�ݡ@q�[*����. ������i�- ��������w���˸���븼y��ۧ[��������7 ����]
213800HVOFXRXVEGDN62 2025-12-31 iso4217:GBP 213800HVOFXRXVEGDN62 2024-12-31 213800HVOFXRXVEGDN62 2025-01-01 2025-12-31 213800HVOFXRXVEGDN62 2024-01-01 2024-12-31 iso4217:GBP xbrli:shares 213800HVOFXRXVEGDN62 2023-12-31 ifrs-full:IssuedCapitalMember 213800HVOFXRXVEGDN62 2023-12-31 ifrs-full:SharePremiumMember 213800HVOFXRXVEGDN62 2023-12-31 ifrs-full:OtherReservesMember 213800HVOFXRXVEGDN62 2023-12-31 ifrs-full:RetainedEarningsMember 213800HVOFXRXVEGDN62 2023-12-31 213800HVOFXRXVEGDN62 2024-01-01 2024-12-31 ifrs-full:IssuedCapitalMember 213800HVOFXRXVEGDN62 2024-01-01 2024-12-31 ifrs-full:Share … search phase. During the year ended 31 December 202 5, the Company recogni se d grant income of £ 585,607 (2024: £ 320,471 ) relating to the three no n - dil utive and non -reimbursable research grant s from the Government of Wall onia in Belgium’s Advanced Therapy Medicinal Products (ATMPs) , the remaining proportion of the €777,281 cash received in 202 4 in re lation to the research grants will be recognis ed as grant income when th e corresponding expenditure has been incu … b iodistribution, and CMC data required to support a n Investigational New Drug application. Prior to initiating GMP m anufacturing, Genflow will ensure full regulatory compliance across all dossier components, including a complete Module 3.2 CMC package and the n on - clinic al pha rmacolog y an d toxicology dataset , to reinforce confiden ce among partners, inves tors, and regulatory agencies. Our ambition is to be positioned to initiate the first proof- of -concept clinica … cal Trial Complementing our human health p rogrammes, Genflow is pioneering the application of SIRT6 -based gene therapy in veterinary medicine. Our canin e healthspan and sarcopenia clinical trial, conducted in partnership with the independent CRO Syngene, involves 28 beagle dog s aged 10 y ears and older t reate d with SIRT6cent, our naked DNA construct optimised for compani on a nimal use. The trial continues to progress according to plan. Interim clinical data are encoura … ge development. In October 202 5, the Co mpany filed a second E uropean pate nt application titled "SIRT6 Variant for NASH" . In April 2 026, the Company filed another patent application entitled "Variants of Sirtuin 6 for the Treatment of Muscular Diseases.". The breadth of our IP position, spanning the centenarian SIRT6 variant itself, its deli
%PDF-1.3 %��������� 3 0 obj > stream x�\ks�Fr��_�2֕dBx?(�eQ�m��6��f�$������������Ӄ�$q��.�����~� ����=��oU����Կ�ޢ�,�������߾ϟ_�eQ�]~�6ok£n�b��>�!�~�?����*��k���p�w������&?��� >�k� �B��1[�G�¿1��U���E �u4 �ȃu����#o���NE@�f�XYmB��hP yi��*;t� R� F���+�� �?�w?Q,�4��y����@��_�_]��ܭ ms�z�m�R��B(��2?��Nő�>��)�� b��VO6�&?IPi��ax>Y�O�FWk��%� �(�{a ���J/c�. !g o�$�q x.�|nl(���|�khd}�����(ٴ%���5� �� g.��ހ�w �I�t�h軙Ϣ��O�V�MQM��)zl�!���l��H�����;懯�]��k��@����0�X���Ԑ�K��f6�� ���� �%�Dz�.��Ʊ�aSx_��>����2�}�*/� �"� �R�ʏr3�o�� ���c�������)hS?�S 7e�u=� ��.PFʢ … ?aڱ��Eq��![ ] ���x]��e�IV��.&�XM�������s}��yu�>:Q:*����y�W�N�����Һ @�� ��RfP�nj�O��{q OO��ԫ��K,���E�7�����������i���F I����q�:�D��|nAا� iCFU �*휨��ʤEVDre�;�� yW�A��o�P���A���˝`�M�[�ʛ���s �� @��h��[Qϯ�w�0_kR��5O�\I�zyX*G�2=A_����]�V t� �O���P��W 9#%:|���?^��QH��n���Şq� M��hׂ��SX��C�.�=���6%���2���/� �e?Z#h�P� �^2��1>=`Ձ!��|0��о}4 >�k�暐Jy8����u�12�gdv�I��� C�(w��}�P�O�$ ^ }����ଈ�hV5r�'�/� 5Wr�&M ~;�-f*�*�1DW�A�)����܅ ��� dͅ'�⡵1�:lj
%PDF-1.4 %��љ 1 0 obj > endobj 2 0 obj > endobj 3 0 obj > stream Emily Hoscik 251231 Genflow Accounts v8 application/pdf 2026-04-30T13:48:17+01:00 Preview 2026-04-30T13:56:09+01:00 macOS Version 15.7.3 (Build 24G419) Quartz PDFContext uuid:76a8909c-b49c-44f8-9aa9-12743292adc4 uuid:e557e1b3-f215-456b-a977-ee598b681932 endstream endobj 4 0 obj > endobj 5 0 obj > endobj 6 0 obj > endobj 7 0 obj > endobj 8 0 obj > endobj 9 0 obj > endobj 10 0 obj > endobj 11 0 obj > endobj 12 0 obj > endobj 13 0 obj > endobj 14 0 obj > endobj 15 0 obj > endobj 16 0 obj > endobj 17 0 obj > endobj 18 0 obj > endobj … �Yo L�܄o1?$? ��\�S���;'h%' ���S ����?��m7 C�慝��$�wvp�5#i�us�ˣ ۫�$]�� �P}rfp�E%��Pn & C>-T+ # �_�z#)~w P� w�����6��0b����)��';Ԝ�g��)~��z둧����*?U�c������ q��TH8�"i�Po�~(}.� �����T)`*S�e f-M|ݣg�u�X���I�䐗3铃P�cPz��E}�{����'O��;sc����F�i��7�����v� �(���0��r���ue��;p��+���45��Zg!d�1i�q����F�c���9j6�eK{�� \7��(�1E }3��D�E1��\��z��8�@ `���� ��.$�͝�z�'��Hu���Hr����>w&��-'T�1���-�цD�O���q�Ʀ�SJ��Y'��9]�5}�r۠�g?��2�'���|�����XO�0� ���F�f�ͮM���
A top team of anti ageing scientists | Genflow | Genflow Biosciences (LON:GENF) (OTCQB:GENFF) LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in, you agree to Lin
%PDF-1.3 %��������� 3 0 obj > stream x�X�n�0��+&]鶒�/���q��Э��@|��@I�Cْ���e�z�y3|��#��#��O vO�O�0�j���탑�v v{�i@�� �4{�n �?� �� ��>�\EL������-o�)ҽ�@��Uzx���i��0U�������������Y�X��쎼��Ԃ ]%� :W隭l����$��;Θ���#����b,��=�C _ JYQ ��#0�A��q%|1��*�wŸ�W�U�S�2���L��2�+H�LB�4J�I36�.�>���#�#��s�ҡ�%�I@@�� � H�8�S2O6�1���P� ��}�/E����(�� î���q'�GKYK�E�����U96W������������&�+\ � ����GB��H ��!u�� ���c��I�����g������|Z �� �"�mm����$�S�ͅ� 1�/��=�M�����=���`�i�G�~�ͨX����!���e�Xm �������!�_a�Mj�.w&����%rkR˲��X�㵼� �:�u��n�� endstream endobj 1 0 obj > endobj 4 0
Media Assets – Genflow Bioscience Skip to main content Skip to footer Company About Leadership Careers Science Genflow BioScience Product Pipeline Clinical Programs Investors Investor Relations Advisers Committees Corporate Governance ESG RNS Major Shareholders News & Media Insights Publications Media Assets Search site Search × Contact Media Assets Table of Contents Genflow Biosciences Logo Dr Eric Leire Genflow Biosciences Logo Logo Icon Colour Logo Reversed Logo White Logo Download Logo set Dr Eric Leire Download Photo Download Photo Dr. Eric Leire brings to the Company a solid b
Asset->js('assets/js/cookie-banner', null, false) }}" as="script">--> --> Genflow Biosciences CEO Reveals the Secrets of Longevity: An Exclusive Interview with Dr Eric Leire | LSE:GENF, OTCQB:GENFF @ element('Front/sign_in_out_buttons') --> UK UK USA AU CA Watch --> My Proactive Feed Alerts Subscriptions Bookmarks Settings Sign In News Browse Latest news Contributors Live Market reports OTC Markets RNS Small caps Poolbeg Pharma has begun an exciting new clinical trial - ICYMI 10:25 13 Jun --> Poolbeg Pharma active on several fronts, powered by capital-light model 10:25 13 Jun --> Why London BT
A longevity bioscience company based in London | Genflow Skip to main content Skip to footer Company About Leadership Careers Science Genflow Bioscience Product Pipeline Clinical Programs Investors Investor Relations Advisers Committees Corporate Governance ESG RNS Major Shareholders News & Media Insights Publications Media Assets Search site Search × Contact Pioneering Novel Therapeutics for a Longer, Healthier Life Our Science Corporate Video Why Genflow Founded in 2020, Genflow Biosciences plc is an emerging leader in the field of longevity research with R&D facilities in Belgium f
Genflow in the Top 50 innovator companies worldwide for 2022 Skip to main content Skip to footer Company About Leadership Careers Science Genflow BioScience Product Pipeline Clinical Programs Investors Investor Relations Advisers Committees Corporate Governance ESG RNS Major Shareholders News & Media Insights Publications Media Assets Search site Search × Contact Genflow in the Top 50 innovator companies worldwide for 2022 Health Tech World has announced its Top 50 health tech innovators of 2022. Here are the top picks of health tech companies who stand out for their unique innovation, ou
Eric Leire On Spotify Podcast – Genflow Bioscience Skip to main content Skip to footer Company About Leadership Careers Science Genflow BioScience Product Pipeline Clinical Programs Investors Investor Relations Advisers Committees Corporate Governance ESG RNS Major Shareholders News & Media Insights Publications Media Assets Search site Search × Contact Eric Leire On Spotify Podcast Dr. Leire discusses some of his background and the amazing things that GenFlow Biosciences are doing to develop gene therapies that slow or reverse aging in humans and dogs. To listen to the podcast clic
A top team of anti ageing scientists | Genflow Skip to main content Skip to footer Company About Leadership Careers Science Genflow Bioscience Product Pipeline Clinical Programs Investors Investor Relations Advisers Committees Corporate Governance ESG RNS Major Shareholders News & Media Insights Publications Media Assets Search site Search × Contact Leadership The Genflow Biosciences team boasts decades of expertise in biotechnology and pharmaceuticals, with extensive experience collaborating with prestigious organizations such as GSK, Pfizer, Schering Plough, and renowned universities in … and from the National Institutes of Health. Her work was awarded the Cozzarelli Prize from PNAS, the prize for research on aging from ADPS/Alianz, France, Prince Hitachi Prize in Comparative Oncology, Japan, and Davey prize from Wilmot Cancer Center. Follow me on Facebook Follow me on Instagram Follow me on TikTok Follow me on YouTube Dr. Eric Verdin Eric Verdin, M.D. has been Chief Executive Officer and President of Buck Institute For Age Research since November 18, 2016. Dr … olism and Molecular Cell. He has received several awards including an Innovator Award from the American Heart Association, a New Scholar in Ageing Award from the Ellison Medical Foundation, and the Helmholtz Young Investigator in Diabetes (HeIDi) Award. His work is supported by grants from the American Heart Association, the Mallinckrodt Foundation, Friedreich’s Ataxia Research Alliance, the Ellison Medical Foundation, and the National Institutes of Health Follow me on Facebo … l degree at the University of Illinois School of Medicine before completing her residency and fellowship at the University of Chicago and Northwestern University, respectively. Her studies on the matters have led to over 150 articles published in prestigious journals such as Nature Reviews Gastroenterology & Hepatology, Gastroenterology, Hepatology , Journal of the American Medical Association (JAMA) , The Lancet and more. Follow me on Facebo